Sign In
Buy IUGNF
$0.0650
-0.0350 (-35.00%)
At Close: Jul 31, 2026
Imugene appoints experienced life sciences CFO in newly created in-house role
11:13pm, Sunday, 17'th Jul 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF) (Imugene Ltd (ASX:IMU, OTC:IUGNF), Imugene Ltd (ASX:IMU, OTC:IUGNF)) has signed up a chief financial officer (CFO) in a newly created in-house role which will see Mik
SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth
Imugene tagged a "buy" by Roth Capital Partners after securing Roche clinical supply deal and patents in Europe and Japan
08:03pm, Thursday, 03'rd Feb 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF)'s recent clinical and patent activities have drawn the attention of Roth Capital Partners, which has placed a “buy” recommendation on the clinical stage cancer-foc
Imugene bolsters executive management team with Dr Steven Cha appointed chief medical officer
06:22pm, Monday, 31'st Jan 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed Dr Steven Cha as its chief medical officer (CMO) and a member of its executive management team. Dr Cha will lead the company's global clinical developmen
Imugene secures Japanese grant notice for Oncolytic Virotherapy CF33 Patent
07:52pm, Sunday, 30'th Jan 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF) has received a notice of grant from the Japanese Patent Office for Patent Application number 2019-507161 which protects its oncolytic virotherapy CF33, including VAXIN
Imugene granted patent for gastric cancer therapy in major oncology market
06:29pm, Thursday, 27'th Jan 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF) has opened the doors to a large and lucrative market for immuno-oncology by securing a Notice of Grant from the European Patent Office for its HER-Vaxx immunotherapy
Imugene farewells its retiring chief medical officer Dr Rita Laeufle
07:31pm, Thursday, 20'th Jan 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF), a clinical stage immuno-oncology company, is set to undergo a shift in personnel with the company's chief medical officer Dr Rita Laeufle retiring from her role at th
Imugene gets A$6.5 million cash boost to support commercial and clinical milestones
05:16pm, Thursday, 06'th Jan 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF) has received a cash boost in the form of a A$6.54 million R&D tax incentive. IMU has received the tax refund as part of the Australian government's R&D tax incentive,
Proactive news headlines including Calima Energy, Imugene Ltd, Lithium Power International and Musgrave Minerals
09:09am, Thursday, 06'th Jan 2022 GlobeNewswire
Sydney, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
Imugene secures patent for HER-Vaxx immunotherapy candidate in South Korea
08:04pm, Wednesday, 05'th Jan 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF) has secured a patent for its HER-Vaxx immunotherapy candidate in South Korea. The clinical-stage immuno-oncology company's newest patent covers the methods of use and
Imugene completes Phase 1a monotherapy dose escalation of PD1-Vaxx and adds industry leaders to management team
06:47pm, Monday, 03'rd Jan 2022
Imugene Ltd (ASX:IMU, OTC:IUGNF) has successfully completed Phase 1a monotherapy dose escalation of PD1-Vaxx and will now proceed to combination dose escalation. The clinical-stage immuno-oncology co
Imugene granted patent protection in China until 2036
07:43pm, Monday, 13'th Dec 2021
Imugene Limited (ASX:IMU, OTC:IUGNF)'s HER-Vaxx immunotherapy is now patent protected in China. The company has received a Notice of Allowance from the People's Republic of China Patent Office for Pa
Why the Imugene (ASX:IMU) share price is charging higher today
11:16pm, Sunday, 12'th Dec 2021 The Motley Fool Australia
The Imugene share price is rising this morning The post Why the Imugene (ASX:IMU) share price is charging higher today appeared first on The Motley Fool Australia .
Imugene secures FDA approval for two clinical trials of promising oncology drug candidates
07:40pm, Sunday, 12'th Dec 2021
Imugene Limited (ASX:IMU, OTC:IUGNF) has obtained US Food and Drug Administration (FDA) consent for clinical trials for two of its oncology treatments, securing Investigational New Drug (IND) approval
Why Bank of Queensland, Imugene, Webjet, and Zip shares are pushing higher
03:23am, Tuesday, 07'th Dec 2021 The Motley Fool Australia
These ASX shares are on form today The post Why Bank of Queensland, Imugene, Webjet, and Zip shares are pushing higher appeared first on The Motley Fool Australia .
